EIGR

Eiger BioPharmaceuticals Inc
2.30
0.26 (12.75%)
2.30
Volume 347
Bid Price 2.06
Ask Price 2.25
News -
Day High

Low
0.96

52 Week Range

High
10.0213

Day Low
Company Name Stock Ticker Symbol Market Type
Eiger BioPharmaceuticals Inc EIGR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.26 12.75% 2.30 04:39:08
Open Price Low Price High Price Close Price Prev Close
2.04
Trades Volume Avg Volume 52 Week Range
10 347 - 0.96 - 10.0213
Last Trade Time Type Quantity Stock Price Currency
04:43:31 58 $ 2.07 USD

Period:

Draw Mode:

Eiger BioPharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 101.37M 44.07M 36.57M $ 12.14M $ -4.32M -1.01 -0.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 180.75k 1.40%

more financials information »

Eiger BioPharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EIGR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.982.271.952.15838,3410.3216.16%
1 Month1.342.271.311.75757,1420.9671.64%
3 Months4.264.620.961.521,154,626-1.96-46.01%
6 Months8.449.890.962.85708,936-6.14-72.75%
1 Year4.5510.02130.965.17714,217-2.25-49.45%
3 Years11.7813.990.967.10449,876-9.48-80.48%
5 Years8.6018.000.967.93328,091-6.30-73.26%

Eiger BioPharmaceuticals Description

Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.